Description
Description:
Postpartum hemorrhage is a leading cause of maternal morbidity and mortality worldwide. Mitigation of postpartum hemorrhage is dependent on identification of risk, readiness, timely identification of hemorrhage, accurate determination of blood loss, and effective treatment. Perinatal nurses must be prepared to participate in all these aspects of care, including the use of tranexamic acid (TXA), an antifibrinolytic agent that has more recently been added to the pharmacologic agents used to reduce blood loss associated with hemorrhage. The purpose of this article is to identify the nurse’s role in management of postpartum hemorrhage (PPH) and to introduce the use of TXA in PPH management as part of the nurse’s role in implementing best practices for PPH.
Learning Objectives:
- Identify the risk factors and clinical presentation of postpartum hemorrhage
- Define the indications and nursing considerations for the use of tranexamic acid.
- Apply the concepts of nursing assessment and intervention to the plan of care in a case study format.
Citation:
Obermeyer, S., Mielke, R. T., & Lederhos, H. L. (2022). The role of perinatal nurses in the use of tranexamic acid during postpartum hemorrhage. Nursing for Women’s Health, 26(1). https://doi.org/10.1016/j.nwh.2021.12.003
Faculty & Faculty Disclosures:
Sarah Obermeyer, PhD, CNM, WHNP-BC, IBCLC
Ruth T. Mielke PhD, CNM, FACNM, WHNP-BC
Heidi L. Lederhos, RN, BS, BSN
- The author and planners for this learning activity report no conflicts of interest or relevant financial relationships. No commercial support was received for this learning activity.
Publication:
Nursing for Women’s Health (NWH), February 2022
Nursing Contact Hours:
1.2 nursing contact hours (of which 0.6 may be applied toward pharmacology) (CNE available until February 6, 2025)
AWHONN Accreditation Statement
The Association of Women’s Health, Obstetric and Neonatal Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Accredited status does not imply endorsement by AWHONN or the ANCC of any commercial products displayed or discussed in conjunction with an educational activity. AWHONN is approved by the California Board of Registered Nursing, provider # CEP580.
Copyright© 2021 by the Association of Women’s Health, Obstetric and Neonatal Nurses. All rights reserved. This material may not be reproduced or transmitted in any form or by any other means, electronic or mechanical, including photocopy recording without permission in writing from the Association of Women’s Health, Obstetric and Neonatal Nurses.
Requests for permission to use or reproduce material from this webinar should be directed to permissions@awhonn.org or mailed to: Permissions, AWHONN, Suite 740S, 1800 M Street, NW, Washington, DC 20036
Keywords: antifibrinolytic, blood loss, maternal morbidity, maternal mortality, obstetric hemorrhage, postpartum hemorrhage, quantitative blood loss, tranexamic acid
Target Audience: Women’s health, obstetric and neonatal nurses.